Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD, ASX: RMD) unveiled its 2030 Strategy at an Investor Day in New York City, aiming to drive growth, profitability, and shareholder returns. The company's ambition is to help over 500 million people achieve their full health potential by 2030. ResMed introduced an updated five-year financial outlook, expecting high-single-digit revenue growth and earnings growth higher than revenue growth.

The 2030 Strategy focuses on three pillars: growing the core sleep apnea franchise, capitalizing on opportunities in broader sleep and breathing health, and investing 7% of revenue into R&D to create an integrated digital ecosystem for home health technology. ResMed plans to leverage its leadership in connected digital health, transforming sleep health, breathing health, and health tech at home through innovative products and digital solutions.

ResMed (NYSE: RMD, ASX: RMD) has launched the AirTouch™ N30i, its first fabric-wrapped CPAP mask. This innovative nasal mask features a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up configuration. The AirTouch N30i combines softness, breathability, and a high-performance seal to deliver exceptional comfort.

In a multi-center study with experienced CPAP users, 92.6% preferred AirTouch N30i for long-term use, and 96.7% rated it appealing or very appealing for its look and feel. The mask incorporates a ComfiSoft™ cushion and fabric-wrapped frame with a fabric seal design coated over silicone. Available in three cushion sizes and two frame sizes, it offers a customized fit. The AirTouch N30i will be available in the U.S. beginning the week of October 28, 2024.

ResMed (NYSE: RMD, ASX: RMD) has unveiled new digital and personalized solutions to improve sleep health. The company has integrated its myAir consumer app with Apple and Android smartwatches, introduced a Generative AI-enabled sleep health assistant named Dawn, and launched new travel gear for CPAP users.

Key features of the updated myAir app include:

• Smartwatch compatibility
• Sleep staging integration
• Personalized coaching
• Holistic health trends

The LUXE range of travel bags for CPAP users will be available in quantities from October 28. These innovations aim to enhance therapy engagement and improve overall health outcomes for sleep apnea patients.

ResMed (NYSE: RMD, ASX: RMD) has announced its 2024 Investor Day, scheduled for September 30, 2024, at the New York Stock Exchange. The event will commence at approximately 1:00 p.m. Eastern Daylight Time and will be accessible both in-person and via a virtual webcast.

This investor day will provide insights into ResMed's 2030 strategy aimed at accelerating growth. Interested parties can find more information, including the live webcast link and an RSVP option for in-person attendance, on the company's investor relations website. A replay of the webcast will be available for 30 days following the event.

ResMed presented 18 supported studies at ERS 2024, including research projecting the impact of vaping, smoking, and air pollution on COPD in Western Europe. Key findings include:

- 88.7 million new COPD hospitalizations projected across Western Europe between 2019-2050
- Vaping projected to incur almost €30 billion additional costs by 2050
- €4.9 trillion projected cumulative cost to support COPD lung conditions by 2050
- 16% projected reduction in risk of death after severe exacerbation for COPD patients using home NIV support

The research highlights the significant health and economic burden of COPD, exacerbated by environmental and behavioral factors. Home non-invasive ventilation (NIV) was found to reduce mortality risk in COPD patients.

ResMed (NYSE: RMD, ASX: RMD) has announced that Chairman and CEO Mick Farrell and Chief Medical Officer Dr. Carlos Nunez will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, September 4, 2024, at approximately 10:00 a.m. EDT at the New York Marriott Marquis.

Investors and interested parties can access the live, audio-only webcast through ResMed's investor relations website. A replay of the webcast will be available for 30 days following the event, accessible approximately 24 hours after the live session ends.

ResMed (NYSE: RMD, ASX: RMD) has expanded its board of directors to 11 members by appointing Christopher DelOrefice, the current CFO of Becton, Dickinson and Company (BD). DelOrefice brings over 30 years of strategic and operational finance expertise to ResMed's board. He will also serve on the board's audit committee. DelOrefice's appointment is effective immediately, and he will stand for re-election at ResMed's annual meeting on November 21, 2024.

Prior to joining BD, DelOrefice held various leadership roles at Johnson & Johnson, including vice president of investor relations and CFO of J&J's consumer and medical device business segments for North America. His experience also includes positions at AstraZeneca, AET Films, and Ametek. ResMed's CEO, Mick Farrell, praised DelOrefice's achievements and leadership capabilities, noting that his financial experience in healthcare and medical technology will complement the existing board members.

ResMed Inc. (NYSE: RMD, ASX: RMD) reported strong Q4 2024 results with year-over-year revenue growth of 9% to $1.2 billion. Key highlights include:

- Gross margin improved 350 bps to 58.5%
- Income from operations increased 38%
- Operating cash flow of $440 million
- Diluted EPS of $1.98; non-GAAP diluted EPS of $2.08
- Quarterly dividend increased 10% to $0.53 per share

For the full fiscal year 2024, ResMed achieved:

- Revenue growth of 11% to $4.7 billion
- Gross margin improvement of 90 bps to 56.7%
- Income from operations increase of 17%
- Operating cash flow of $1.4 billion
- Diluted EPS of $6.92; non-GAAP diluted EPS of $7.72

The company reported strong performance across all sectors, driven by high demand for its products and software solutions.

ResMed (NYSE: RMD, ASX: RMD) announces it will release its fourth quarter fiscal year 2024 earnings on August 1, 2024, after the NYSE closes. Management will host a webcast to discuss the financial and operational results. Investors and stakeholders will gain insights into the company's performance and future outlook.